Patients with Parkinson's Disease Patients Are Often Administered a Catechol-O-Methyltransferase

Patients with Parkinson's disease patients are often administered a catechol-O-methyltransferase (COMT) inhibitor because COMT

A) interacts poorly with other drugs frequently used to treat Parkinson's disease.
B) metabolizes a major portion of the administered l-DOPA before it reaches the brain.
C) prevents the conversion of tyrosine to DOPA.
D) builds up very quickly in the body and can lead to adverse reactions.